Gil Tae Wie

Selecxine, Inc. Co Ltd. is a bio start-up founded in December 2018 in an undisclosed location. The company is based in Seoul, South Korea. The South Korean company specializes in developing monoclonal antibodies using platform technology. Selecxine develops antibodies that bind to specific epitopes on target proteins for modification and amplification of the desired signal from bifunctional biomolecules such as cytokines and cytokine receptors. The company's novel candidate, SLC-3010, is an immune-mediated anti-cancer therapeutic that selectively stimulates anti-tumor immune response. The efficacy of SLC-3010 in eradicating various types of tumors was thoroughly demonstrated through various in vitro and in vivo experiments. Selecxine is actively developing subsequent pipelines based on the well-established in-house platform. The company was founded in 2018, and the CEO is Jun-Young Lee.